Low Seroprevalent Species D Adenovirus Vectors as Influenza Vaccines

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Weaver, Eric A ^a   Barry, Michael A ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VACCINE; ADENOVIRUS VECTOR; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ;

ADENOVIRUS; ADENOVIRUS 26; ADENOVIRUS 28; ADENOVIRUS 48; ADENOVIRUS 5; ADENOVIRUS 6; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DOSE TITRATION; FEMALE; IMMUNITY; IN VIVO STUDY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; MOUSE; NONHUMAN; SEROPREVALENCE; SPECIES DIFFERENCE;

ADENOVIRIDAE; ANIMALS; GENETIC VECTORS; HEMAGGLUTININS, VIRAL; IMMUNITY, INNATE; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; VIRUS REPLICATION;

EID: 84882762549     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073313     Document Type: Article

References (44)

1. WHO (2009) Influenza Fact Sheet.
2. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, et al. (2007) The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25: 5086-5096. doi:10.1016/j.vaccine.2007.03.046. PubMed: 17544181.
3. Nicholson KG, McNally T, Silverman M, Simons P, Zambon MC, (2003) Influenza-related hospitalizations among young children in Leicestershire. Pediatr Infect Dis J 22: S228-S230. PubMed: 14551481.
4. Kilbourne ED, Smith C, Brett I, Pokorny BA, Johansson B, et al. (2002) The total influenza vaccine failure of 1947 revisited: major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic. Proc Natl Acad Sci U S A 99: 10748-10752. doi:10.1073/pnas.162366899. PubMed: 12136133.
5. Potter CW, Jennings R, Clark A, (1977) The antibody response and immunity to challenge infection induced by whole, inactivated and tween-ether split influenza vaccines. Dev Biol Stand 39: 323-328. PubMed: 604115.
6. Clements ML, Betts RF, Tierney EL, Murphy BR, (1986) Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 24: 157-160. PubMed: 3722363.
7. Muszkat M, Friedman G, Schein MH, Naveh P, Greenbaum E, et al. (2000) Local SIgA response following administration of a novel intranasal inactivated influenza virus vaccine in community residing elderly. Vaccine 18: 1696-1699. doi:10.1016/S0264-410X(99)00509-5. PubMed: 10689151.
8. Muszkat M, Greenbaum E, Ben-Yehuda A, Oster M, Yeu'l E, et al. (2003) Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine. Vaccine 21: 1180-1186. doi:10.1016/S0264-410X(02)00481-4. PubMed: 12559796.
9. Subbarao K, (1999) Influenza vaccines: present and future. Adv Virus Res 54: 349-373. doi:10.1016/S0065-3527(08)60371-1. PubMed: 10547679.
10. Bardiya N, Bae JH, (2005) Influenza vaccines: recent advances in production technologies. Appl Microbiol Biotechnol 67: 299-305. doi:10.1007/s00253-004-1874-1. PubMed: 15660212.
11. Bridges CB, Harper SA, Fukuda K, Uyeki TM, Cox NJ, et al. (2003) Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 52: 1-34; quiz CE31-34.
12. Check E, (2005) Avian flu special: is this our best shot? Nature 435: 404-406. doi:10.1038/435404a. PubMed: 15917769.
13. Daems R, Del Giudice G, Rappuoli R, (2005) Anticipating crisis: towards a pandemic flu vaccination strategy through alignment of public health and industrial policy. Vaccine 23: 5732-5742. doi:10.1016/j.vaccine.2005.10.011. PubMed: 16271423.
14. Tree JA, Richardson C, Fooks AR, Clegg JC, Looby D, (2001) Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 19: 3444-3450. doi:10.1016/S0264-410X(01)00053-6. PubMed: 11348709.
15. Schuchat, Anne (2011) H1N1 Preparedness: An Overview of Vaccine Production and Distribution HHS Home > ASL Home > Testimony. http://www.hhs.gov/asl/testify/2009/11/t20091118b.html: HHS News Releases.
16. Osterholm MT, Kelley NS, Sommer A, Belongia EA, (2012) Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12: 36-44. doi:10.1016/S1473-3099(11)70295-X. PubMed: 22032844.
17. Sasaki S, He XS, Holmes TH, Dekker CL, Kemble GW, et al. (2008) Influence of prior influenza vaccination on antibody and B-cell responses. PLOS ONE 3: e2975. doi:10.1371/journal.pone.0002975. PubMed: 18714352.
18. Belsey MJ, de Lima B, Pavlou AK, Savopoulos JW, (2006) Influenza vaccines. Nat Rev Drug Discov 5: 183-184. doi:10.1038/nrd1988. PubMed: 16557657.
19. Bernstein DI, Yan L, Treanor J, Mendelman PM, Belshe R, (2003) Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children. Pediatr Infect Dis J 22: 28-34. doi:10.1097/00006454-200301000-00010. PubMed: 12544405.
20. Tabain I, Ljubin-Sternak S, Cepin-Bogović J, Markovinović L, Knezović I, et al. (2012) Adenovirus respiratory infections in hospitalized children: clinical findings in relation to species and serotypes. Pediatr Infect Dis J 31: 680-684. PubMed: 22517338.
21. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, et al. (2007) Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81: 4654-4663. doi:10.1128/JVI.02696-06. PubMed: 17329340.
22. Appaiahgari MB, Pandey RM, Vrati S, (2007) Seroprevalence of Neutralizing Antibodies to Adenovirus Type 5 among Children in India: Implications for Recombinant Adenovirus-Based Vaccines. Clin Vaccine Immunol 14: 1053-1055. doi:10.1128/CVI.00173-07. PubMed: 17596429.
23. Holterman L, Vogels R, van der Vlugt R, Sieuwerts M, Grimbergen J, et al. (2004) Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol 78: 13207-13215. doi:10.1128/JVI.78.23.13207-13215.2004. PubMed: 15542673.
24. Esparza J, (2013) Progress in the development of an adenovirus 26 vector platform for HIV vaccines. Expert Rev Vaccines 12: 477-480. doi:10.1586/erv.13.26. PubMed: 23659296.
25. Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, et al. (2011) International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29: 5203-5209. doi:10.1016/j.vaccine.2011.05.025. PubMed: 21619905.
26. Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, et al. (2010) International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28: 950-957. doi:10.1016/j.vaccine.2009.10.145. PubMed: 19925902.
27. Anne Schuchat MDMD, (2011) H1N1 Preparedness: An Overview of Vaccine Production and Distribution.
28. Weaver EA, Rubrum AM, Webby RJ, Barry MA, (2011) Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin. PLOS ONE 6: e18314. doi:10.1371/journal.pone.0018314. PubMed: 21464940.
29. Weaver EA, Hillestad ML, Khare R, Palmer D, Ng P, et al. (2011) Characterization of species C human adenovirus serotype 6 (Ad6). Virology 412: 19-27. doi:10.1016/j.virol.2010.10.041. PubMed: 21251688.
30. Zhang J, Tarbet EB, Feng T, Shi Z, Van Kampen KR, et al. (2011) Adenovirus-vectored drug-vaccine duo as a rapid-response tool for conferring seamless protection against influenza. PLOS ONE 6: e22605. doi:10.1371/journal.pone.0022605. PubMed: 21818346.
31. Gitelman AK, Kaverin NV, Kharitonenkov IG, Rudneva IA, Zhdanov VM, (1984) Changes in the antigenic specificity of influenza hemagglutinin in the course of adaptation to mice. Virology 134: 230-232. doi:10.1016/0042-6822(84)90288-5. PubMed: 6200993.
32. Schild GC, Oxford JS, de Jong JC, Webster RG, (1983) Evidence for host-cell selection of influenza virus antigenic variants. Nature 303: 706-709. doi:10.1038/303706a0. PubMed: 6190093.
33. Wood JM, Kawaoka Y, Newberry LA, Bordwell E, Webster RG, (1985) Standardization of inactivated H5N2 influenza vaccine and efficacy against lethal A/Chicken/Pennsylvania/1370/83 infection. Avian Dis 29: 867-872. doi:10.2307/1590681. PubMed: 4074253.
34. Rappuoli R, Dormitzer PR,. (2012) Influenza: options to improve pandemic preparation. Science 336: 1531-1533. doi:10.1126/science.1221466. PubMed: 22723412.
35. Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, de Wit E, et al. (2012) Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336: 1534-1541. doi:10.1126/science.1213362. PubMed: 22723413.
36. Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, et al. (2012) Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486: 420-428. PubMed: 22722205.
37. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, et al. (2012) Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482: 89-93. doi:10.1038/nature10766. PubMed: 22217938.
38. Barouch DH, O'Brien KL, Simmons NL, King SL, Abbink P, et al. (2010) Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 16: 319-323. doi:10.1038/nm.2089. PubMed: 20173752.
39. Liu J, Ewald BA, Lynch DM, Denholtz M, Abbink P, et al. (2008) Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol 82: 4844-4852. doi:10.1128/JVI.02616-07. PubMed: 18337575.
40. Lin SW, Cun AS, Harris-McCoy K, Ertl HC, (2007) Intramuscular rather than oral administration of replication-defective adenoviral vaccine vector induces specific CD8+ T cell responses in the gut. Vaccine 25: 2187-2193. doi:10.1016/j.vaccine.2006.11.044. PubMed: 17229501.
41. Tatsis N, Lasaro MO, Lin SW, Haut LH, Xiang ZQ, et al. (2009) Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens. J Immunol 182: 6587-6599. doi:10.4049/jimmunol.0900317. PubMed: 19414814.
42. Campos SK, Parrott MB, Barry MA, (2004) Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector. Molecular Therapy 9: 943-955.
43. Campos SK, Barry MA, (2004) Rapid construction of capsid-modified adenoviral vectors through bacteriophage lambda red recombination. Hum Gene Ther 15: 1125-1130. doi:10.1089/hum.2004.15.1125. PubMed: 15610612.
44. Sprangers MC, Lakhai W, Koudstaal W, Verhoeven M, Koel BF, et al. (2003) Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 41: 5046-5052. doi:10.1128/JCM.41.11.5046-5052.2003. PubMed: 14605137.